Amneal Pharmaceuticals Hits New 52-Week High of $18.39

Amneal Pharmaceuticals, Inc. has reached a significant milestone by hitting a new 52-week high of USD 18.39 on July 17, 2026. This achievement underscores the company's strong performance in the pharmaceuticals and biotechnology sector, particularly notable given its market capitalization of USD 3,728 million, categorizing it as a small-cap stock. Over the past year, Amneal Pharmaceuticals has demonstrated impressive growth, with a remarkable 160.58% increase in its stock price, significantly outperforming the S&P 500, which recorded an 18.43% gain during the same period. The company's price-to-earnings (P/E) ratio stands at 22.00, reflecting its valuation in the market. Despite the positive price movement, the company has a dividend yield of 0.00% and a debt-to-equity ratio of -32.15, indicating a unique financial structure. However, the return on equity is notably low, at -999,999.00%, and the price-to-book ratio is at -52.66, suggesting areas for potential improvement. Overall, Amneal Pharmaceuticals' recent performance highlights its current position in the market and the dynamics of the pharmaceuticals and biotechnology industry.